ArticleApplied and environmental microbiology2023
The First Lanthipeptide from Lactobacillus iners, Inecin L, Exerts High Antimicrobial Activity against Human Vaginal Pathogens.
Article in Applied and environmental microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- Trial
- Utilizing natural competence to genetically manipulateApplied and environmental microbiology · 2026Article
- Diversity and Classification of the Actinopeptins: A New Family of Lanthipeptides Within the Genomes from the Phylum Actinomycetota.Antibiotics (Basel, Switzerland) · 2026Article
- High-quality draft genome sequence data ofData in brief · 2026Article
- Impact of prebiotics, probiotics, and postbiotics on maternal and fetal health: mechanisms, efficacy, and safety across pregnancy.Pediatric research · 2026Review
- Global Genomic Landscapes ofLife (Basel, Switzerland) · 2025Article
- Practical media formulations for rapid growth ofApplied and environmental microbiology · 2025Article
- Metagenomic analysis reveals the novel role of vaginal Lactobacillus iners in Chinese healthy pregnant women.NPJ biofilms and microbiomes · 2025Article
- Heterologous Expression and Characterization of Estercin A, a Class II Lanthipeptide Derived fromJournal of natural products · 2025Article
- Efficient utilization of Shuanghuanglian medicine residues by microbial transformation with flavonoid glycosides-hydrolyzing strains.Frontiers in microbiology · 2025Article
- The alleviating effects and mechanisms ofFrontiers in veterinary science · 2025Article
- Effects of Dietary Quality on Vaginal Microbiome Composition Throughout Pregnancy in a Multi-Ethnic Cohort.Nutrients · 2024Article
- Protective Mechanisms of Vaginal Lactobacilli against Sexually Transmitted Viral Infections.International journal of molecular sciences · 2024Review
- Characterization of a LanC-free pathway for the formation of an ll-MeLan residue and anChemical science · 2024Article
- Facile Method for Determining Lanthipeptide Stereochemistry.Analytical chemistry · 2024Article
- Microbiota dynamics, metabolic and immune interactions in the cervicovaginal environment and their role in spontaneous preterm birth.Frontiers in immunology · 2023Review
- Breakthroughs in the development of antibiotics, antifungals and antiparasitics targeting the pathogens' respiratory chain.Critical reviews in biochemistry and molecular biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaginal infections continue to be a serious public health issue, and developing new approaches to address antibiotic-resistant pathogens is an urgent task. The dominant vaginal Lactobacillus species and their active metabolites (e.g., bacteriocins) have the potential to defeat pathogens and help individuals recover from disorders. Here, we describe for the first time a novel lanthipeptide, inecin L, a bacteriocin from Lactobacillus iners with posttranslational modifications. The biosynthetic genes of inecin L were actively transcribed in the vaginal environment. Inecin L was active against the prevailing vaginal pathogens, such as Gardnerella vaginalis and Streptococcus agalactiae, at nanomolar concentrations. We demonstrated that the antibacterial activity of inecin L was closely related to the N terminus and the positively charged His13 residue. In addition, inecin L was a bactericidal lanthipeptide that showed little effect on the cytoplasmic membrane but inhibited the cell wall biosynthesis. Thus, the present work characterizes a new antimicrobial lanthipeptide from a predominant species of the human vaginal microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.